current medical research and opinion journal

Current Medical Research and Opinion

Subject Area and Category

• Medicine (miscellaneous)

Taylor and Francis Ltd.

Publication type

14734877, 03007995

Information

How to publish in this journal

[email protected]

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Leave a comment

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Follow us on @ScimagoJR Scimago Lab , Copyright 2007-2022. Data Source: Scopus®

Cookie settings

Cookie Policy

Legal Notice

Privacy Policy

• English Editing
• Translation
• Figure Services
• Poster Preparation
• Video Abstracts
• My Searches
• My Journals

Current Medical Research & Opinion

Aims and scope.

Current Medical Research & Opinion publishes original research on new and existing drugs, drug-delivery devices and therapies. Contributions are welcomed in the form of: Full-length articles reporting the original results of Phase II-IV studies and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear and significant clinical relevance, at the discretion of the Editors. Information on pharmaceutical preparations and medical devices, including therapeutic diagnostic (theranostic) products and over-the-counter medicines, as well as ethical pharmaceutical products and prescription-only medicines. Studies with a strong link to clinical practice, both in primary, secondary (hospital) and tertiary (specialist) care settings, particularly those with significant implications for clinical prescribing by primary care physicians and general practitioners, as well as hospital physicians and specialists. Review articles on new and existing drugs; drug classes and therapeutic areas; and disease states. Brief Reports, Commentaries and Research Letters that meet the above criteria, and Letters to the Editor briefly commenting on work previously published in the journal. (A full description of types of article is included on page 8 of the downloadable MS Word document.) Supplements are also published and encouraged. These include both stand-alone and in-journal supplements based on symposia proceedings (sponsored workshops, meetings, webinars, webcasts, etc.), or collected articles on specific drugs or disease states. Enquiries from potential guest editors, meeting organizers and sponsors are welcomed. Supplements undergo the same rigorous peer review used for regular CMRO articles. Supplements must adhere to CMRO's transparency policy and acknowledgments requirements.

Responsiveness Not Provided

Publication speed average, submission fees $.

None listed

Publication or page charges $

Color charges.

Colour figures will only be accepted if colour is deemed to be essential, at the discretion of the Editor-in-Chief and Publisher. Use of colour in the printed journal will entail a charge on a scale related to the additional costs of colour reproduction.

Open Access Policy

Open access available yes.

The publisher will deposit to PubMed Central (PMC) and UK PubMed Central (UKPMC) author manuscripts reporting NIH or Wellcome Trust funded research on specific request by the author. Paid, immediate open access is not listed as an option for this journal.

Verified journal

This journal is included in the JournalGuide whitelist of reputable titles. Learn more here.

General information

Journal profile.

This journal's profile page has not been yet been claimed by an official representative.

More actions

Journal common names.

Do you know this journal by another common name or abbreviation? Enter it here and use it for your future searches

Submissions

Submission preparation checklist.

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

• The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
• The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
• Where available, URLs for the references have been provided.
• The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
• The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.

Author Guidelines

Please note that this journal only publishes manuscripts in English.

JCMRO accepts the following types of article:

• Full-length articles
• Review articles (systematic and narrative) on new and existing drugs; drug classes and therapeutic areas; and disease states; meta-analyses, network meta-analyses, indirect and mixed treatment comparisons.
• Brief Reports, Commentaries and Research Letters that meet the above criteria, and Letters to the Editor briefly commenting on work previously published in the journal.

Peer review

Journal is committed to peer-review integrity and upholding the highest standards of review. Once your paper has been assessed for suitability by the editor, it will then be double blind peer-reviewed by independent, anonymous expert referees.

Author Instruction

Ethics in publishing For information on Ethics in publishing and Ethical guidelines for journal publication see Publication Ethics .

Conflict of interest All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work..

Submission declaration and verification Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck

Changes to authorship This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts: Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed. After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Copyright This journal offers authors a choice in publishing their research: Open Access and Subscription.

For Subscription articles Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright )

For Open Access articles Upon acceptance of an article, authors will be asked to complete an 'Exclusive License.

Role of the funding source You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Open access This journal offers authors a choice in publishing their research:

Open Access • Articles are freely available to both subscribers and the wider public with permitted reuse • An Open Access publication fee is payable by authors or their research funder Subscription • Articles are made available to subscribers as well as developing countries and patient groups through our access programs

All articles published Open Access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses: Creative Commons Attribution : lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

The publication fee for this journal is $260 , excluding taxes.

Language (usage and editing services) Please write your text in good English

Submission Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files, which is used in the peer-review process. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

Use of word processing software It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Introduction State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Theory/calculation A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results Results should be clear and concise.

Discussion This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information   Title Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible. Author names and affiliations Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author. Corresponding author Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.

Abstract A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Keywords Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Acknowledgements Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Figure captions Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title ( not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

Citation in text Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference style Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given. Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....' List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text. Examples: Reference to a journal publication: [1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 163 (2010) 51–59. Reference to a book: [2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000. Reference to a chapter in an edited book: [3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.

Editor's Choice: AI Tools to Improve Access to Reliable Health Information

• Original Investigation Non–High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events Feitong Wu, PhD; David R. Jacobs, PhD; Stephen R. Daniels, MD, PhD; et al cme

Just Published

• Non–HDL-C Levels From Childhood to Adulthood and CVD Events Feitong Wu, PhD; et al. Original Investigation online first has active quiz Feitong Wu, PhD; et al.
• Manufacturer Payments to Cardiologists and Use of Devices Sanket S. Dhruva, MD, MHS; et al. Research Letter online first Sanket S. Dhruva, MD, MHS; et al.
• Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability Viktor H. Ahlqvist, PhD; et al. Original Investigation has active quiz Viktor H. Ahlqvist, PhD; et al.
• Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a) Steven E. Nissen, MD; et al. Original Investigation online first Steven E. Nissen, MD; et al.
• Cardiac Function Before Sepsis and Clinical Outcomes Stuthi Iyer, MPH; et al. Research Letter online first Stuthi Iyer, MPH; et al.
• Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus Fatimah S. Dawood, MD; et al. Viewpoint online first free access Fatimah S. Dawood, MD; et al.
• Good Enough Lauren Rissman, MD A Piece of My Mind online first free access Lauren Rissman, MD
• Including Pregnant and Lactating Women in Clinical Research Margaret Foster Riley, JD Viewpoint online first free access Margaret Foster Riley, JD
• Trading Places, Becoming One Rafael Campo, MD, MA Editor's Note free access Rafael Campo, MD, MA
• Data Checks Before Registering Study Protocols for Health Care Database Analyses Shirley V. Wang, PhD; et al. Viewpoint online first free access Shirley V. Wang, PhD; et al.
• Tilt Table Testing William P. Cheshire, MD; et al. JAMA Diagnostic Test Interpretation online first has active quiz William P. Cheshire, MD; et al.
• Does This Patient Have Alcohol Use Disorder? Evan Wood, MD, PhD; et al. The Rational Clinical Examination has active quiz Evan Wood, MD, PhD; et al.
• Systemic Lupus Erythematosus Caroline H. Siegel, MD, MS; et al. Review online first has active quiz has multimedia Caroline H. Siegel, MD, MS; et al.
• Risk Assessment and Prevention of Falls in Older Community-Dwelling Adults Cathleen S. Colón-Emeric, MD, MHS; et al. Review online first has active quiz has multimedia Cathleen S. Colón-Emeric, MD, MHS; et al.
• Guidelines on Falls Prevention in Older Adults Peggy B. Leung, MD; et al. JAMA Clinical Guidelines Synopsis online first has active quiz has multimedia Peggy B. Leung, MD; et al.

Latest from the USPSTF

• USPSTF Recommendation: Primary Care Interventions to Prevent Child Maltreatment
• USPSTF Recommendation: Screening for Speech and Language Delay and Disorders
• USPSTF Recommendation: Screening and Preventive Interventions for Oral Health in Adults
• 40,126 Views Brain Waves Appear to Wash Out Waste During Sleep
• 30,084 Views Provision of Medications for Self-Managed Abortion Before and After the Dobbs Decision
• 27,486 Views Effect of Tirzepatide on Maintenance of Weight Reduction
• 26,987 Views Study Provides Insight Into ME/CFS
• 25,392 Views Industry Payments to US Physicians by Specialty and Product Type
• 24,611 Views Pharmacotherapy and Mortality in Individuals With ADHD
• 24,009 Views Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality
• 22,149 Views Questions Surround Blood Tests That Claim to Screen for Multiple Cancers
• 22,106 Views Stroke Risk After COVID-19 Bivalent Vaccination in US Older Adults
• 21,768 Views International Consensus Criteria for Pediatric Sepsis and Septic Shock
• 717 Citations Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
• 652 Citations Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization
• 609 Citations Pancreatic Cancer
• 598 Citations Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals
• 591 Citations USPSTF Recommendation: Screening for Colorectal Cancer
• 511 Citations Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
• 456 Citations The Leading Causes of Death in the US for 2020
• 444 Citations Effect of Intermediate- vs Standard-Dose Anticoagulation on Outcomes of Patients With COVID-19
• 440 Citations Association Between IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
• 409 Citations Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by Omicron and Delta Variants
• Register for email alerts with links to free full-text articles
• Access PDFs of free articles
• Manage your interests
• Save searches and receive search alerts

Journal of Current Medical Research and Opinion Latest Publications

Total documents, published by innovative journal.

• Latest Documents
• Most Cited Documents
• Contributed Authors
• Related Sources
• Related Keywords

Real-world clinical experience of extended half-life recombinant factor VIII Fc fusion protein (rFVIIIFc) in comparison to conventional factor products in patients with severe hemophilia A

Introduction: The recombinant factor FVIII Fc fusion protein (rFVIIIFc) is a first-in-class extended half-life FVIII product to treat patients with hemophilia A. The safety, efficacy and prolonged half-life of rFVIIIFc was demonstrated in the phase 3 studies A-LONG, Kids A-LONG and the extension study ASPIRE. Despite robust efficacy and safety data of rFVIIIFc therapy from clinical trials, evidence on the effectiveness of rFVIIIFc use in real-world remains scarce. Our analysis aimed at investigating the effectiveness of prophylactic rFVIIIFc treatment in routine clinical use in Germany. Material and Methods: Twenty-seven patients with severe hemophilia A, who switched from prophylaxis with conventional recombinant factor VIII (rFVIII) products to rFVIIIFc, were included. Annualized bleeding rates, factor consumption, number of injections and adherence to prophylaxis were compared. The retrospective period prior switching to rFVIIIFc was three years, while the mean follow-up period after switching to rFVIIIFc was 24.9 months. Results: Switching to rFVIIIFc led to a 33.7% reduction in mean annualized number of injections and a 18.3% reduction in mean annualized factor consumption while maintaining low bleeding rates. The mean annualized bleeding rate (ABR) was 2.5 and 1.7 for rFVIII and rFVIIIFc, respectively. The adherence improved from 87% to 94%. During the follow-up period eleven surgeries were performed; all with a hemostatic response rated as excellent. No FVIII inhibitor formation after switching to rFVIIIFc has been detected. Conclusion: Real-world treatment with rFVIIIFc was associated with substantial reductions in consumption and injection frequenies while maintaining low bleeding rates supporting safety and efficacy data from clinical trials.

Convalescent Plasma to Limit Coronavirus Associated Complications: A Proof of Concept Phase-2 Clinical Study at a designated COVID-19 hospital in Mumbai city

Objective: With few treatment options available to manage coronavirus disease 2019 (COVID-19), health systems devised strategies to manage covid-19 using repurposed drugs and revisiting older strategies, such as convalescent plasma. This study was planned to evaluate safety and efficacy of Anti-SARS-CoV-2 convalescent plasma in hospitalized subjects with COVID-19. Method: An open label, single centre, two arm, prospective, randomised, controlled exploratory phase 2 study was conducted at a covid-19 designated center. 20 subjects (≥18 years) were admitted to hospital (screened 15 June to 27 July 2020) with confirmed moderate covid-19 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen (PaO2/FiO2) ratio between 200 mm Hg and 300 mm Hg or a respiratory rate of more than 24/min with oxygen saturation 93% or less on room air): 10 subjects were assigned to convalescent plasma with standard treatment (test arm) and 10 subjects to standard treatment only (control arm). Subjects in the test arm received either single or two doses of convalescent plasma 24 hours apart based on their clinical condition as per investigator’s discretion. Results: Subjects in test arm showed earlier resolution of symptoms of fever, shortness of breath and cough and the mean duration for RT-PCR test turning negative was better in the test arm. One subject in the control arm progressed to severe ARDS, while none in test arm progressed to severe ARDS. There was no difference in the use of respiratory support (invasive and non-invasive ventilation) between the 2 arms. There was no mortality observed in the study and no serious adverse reaction observed with the transfusion of convalescent plasma in the study. Conclusion: This was an exploratory proof of concept study to explore the effectiveness of convalescent plasma in COVID-19 subjects and sample size was not large enough to detect a statistically significant difference however subjects in test arm of this study showed better outcomes in few of the efficacy parameters as compared to subjects in control arm. The use of convalescent plasma transfusion was also observed to be safe.

Understanding the “Conflict of Interest

According to Wikipedia, ‘Çonflict of interest’ is a set of circumstances that creates a risk that professional judgement or actions regarding a primary interest will be unduly influenced by a secondary interest' [1]. It may be broadly described as conditions which may influence one’s judgement in a situation (primary interest) for some other gain (secondary interest), this may be financial or non-financial . It is of importance to understand that having a secondary gain is not wrong but these gains should not be illegal. This pertains to delivery of patient care, teaching and research in the medical profession.

Child Abuse and Neglect: An Overview

Child abuse and neglect are serious global problems and can be in the form of physical, sexual, emotional or just neglect in providing for the child's needs. These factors can leave the child with serious, long-lasting psychological damage. Child maltreatment is a complex life experience occurs when a parent or caregiver does an intentional or potential damage to a child, including acts of commission and omission. Child abuse is not an uncommon event, but it is not always recognized. Identifying the real number of maltreated children is a challenge because of the large variability in reported prevalence data across studies. It is associated with important economic and social costs (such as physical and mental health, productivity losses, child welfare, criminal justice and special education costs) due to its high prevalence and its long-term and short-term consequences.

Oncotherapeutics: A General Overview

Experimental oncotherapeutics programs have been in place at major academic centres for over four decades. The emergence of molecular targeting agents and the recent introduction of immuno-oncology drugs have expanded the scope and eligibility for first-in-human trials. Improved understanding of tumor biology coupled with the ability to screen for tumor associated targets, as well as, genetic alterations have heralded the era of personalized (personalized or precision) cancer treatment. Molecular targeting agents with their improved tolerability and sustained responses compared to conventional cytotoxic chemotherapy have contributed to remarkable improvements in clinical outcomes Dramatic phase 1 observations of anti-tumor activity of novel molecules in the relapsed or refractory setting have ofen led to their investigation as monotherapy or in combinatorial strategies early in the course of cancer treatment. Studies have thus evolved from the traditional role of dose and toxicity-fnding studies to innovative enrichment study designs which match patients with study agents, thus increasing the potential of clinical efcacy, even in the early dose escalation setting.

Interactions- Readdressing the issue

Broadly drugs include all the chemical substances excluding food that affect the bodily processes. The drug is considered to be a medicine if it benefits the body. Whereas, if the drug is injurious to the body, it’s considered as a poison. Therefore, the same chemical can be a boon or curse with respect to the situation, condition of use, dosage and the individual using it. In this contemporary healthcare era, a huge number of medications are formulated each year and new interactions between drugs are reported every now and then. As a result, it is no more practical for doctors to be dependent on the memory alone to avoid possible drug interactions. Changes in absorption, distribution, metabolism or elimination of drugs are referred to as pharmacokinetic interactions, resulting in alteration in the level of drugs and its metabolites. The effect of drug changes from person to person than expected because it causes different reaction when a drug reacts with the food or dietary supplements they take (drug -food interaction). So, the effect of the drug is altered by means of increasing, decreasing, or producing a new effect which cannot be produced on its own the effect caused by food or dietary supplements. These interactions may occur due to accidental misuse or due to other factors such as lack of knowledge about it. This review provides a comprehensive literature review on various drug interaction. Generally, drug food interactions are neglected and not well defined but it can cause mild to serious effects. However, all clinicians, pharmacists and nurses should be aware of drug interaction to avoid the consequences caused by drug interactions.

A Study To Determine The Effect Of Egg Albumin Dressing On Peristomal Wound Healing of the Colostomy Patients In A Selected Hospital, Kolkata, West Bengal

The researcher conducted a quasi experimental study to evaluate the effect of egg albumin dressing on peristomal wound healing in a selected hospital, Kolkata, with the objectives to assess the peristomal skin condition of colostomy patients before treatment, to evaluate the effect of egg albumin dressing on healing of peristomal area and reduction of pain, to find out the association between the peristomal wound healing and selected variables. The final study was conducted at Curzon ward, Victoria ward of SSKM hospital, Kolkata. Ethical permission was sought out from Ethical Committee of SSKM hospital, Kolkata. Informed consent was taken from all respondents. The sample was selected according to their selected criteria. The sample selection was done by purposive sampling. They were randomly assigned into two groups (experimental and control group) in 1:1 ratio. The study concluded with its limitations, implications and recommendations for conducting a study may be conducted for a longer duration of observation with the treatment.

Peripheral Nerve Blockade and Botox Treatment in Chronic Migraine: A Comparative Study

Migraine is the most commonly encountered disabling headache. Chronic migraine significantly affects the quality of life and reduces the ability to attend work and social events, and consequently becomes an increasing economic burden.In recent years, peripheral nerve block with botulinum toxin A (botox) and local analgesics has been included in alternative treatment regimens.In cases of chronic migraine, botox is injected into the facial area, maxillary and mandibular nerve, and the head and neck muscles.Recent methods such as great occipital nerve (GON), and lesser occipital nerve, supra orbital nerve (SON), sphenopalatine ganglion blockade and trigeminal ganglion blockade have been applied using local analgesics. GON and SON blockade are the most frequently used of these methods. Studies related to these methods have shown a decrease in the frequency and severity of migraine pain.The results of this study showed that both GON and SON blockade and long-term application of BTX-A treatment were highly effective in the treatment of chronic migraine and both treatment methods had a similar level of effectiveness.That the follow-up period of this study was longer than in previous research can be considered a strong aspect of the study.

Rosuvastatin and Fenofibrate Combination in The Treatment of Mixed Hyperlipidemia: A Narrative Review

Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL-C). Though useful in lowering LDL-C, therapy with rosuvastatin is insufficient in optimizing the overall lipid profile, thus putting the patient at risk of residual cardiovascular risk. A combination of statin with other lipid-modifying agents has been used with more efficient lipid control and cardiovascular risk prevention. Of these, fenofibric acid is the most frequently used, along with rosuvastatin. Methods: Authors conducted a literature search of published literature to assess the use of rosuvastatin and fenofibrate combination in the management of mixed hyperlipidaemia. Results and discussion: The authors selected a total of 46 articles to be included in the review. Due to the small number of articles and heterogeneity on the combination of rosuvastatin and fenofibrate combination in mixed hyperlipidemia, the findings herein are presented using narrative summaries. Based on the thorough assessment of the selected literature, the essential themes that emerged from the review include safety and efficacy of rosuvastatin and fenofibrate combination, place of therapy of rosuvastatin, and fenofibrate combination, and potential cardiovascular risk reduction with rosuvastatin and fenofibrate combination.   Conclusion: Based on the review, the authors suggested that the combination therapy with fenofibric acid was beneficial, well-tolerated with a similar safety profile compared with statin monotherapy. The combination therapy of moderate dose rosuvastatin and fenofibric acid led to a reduction of cardiovascular risk factors via several pathways.

Comparative study between H. Pylori induced and NSAIDs induced peptic ulcer

The use of Non-steroidal anti-inflammatory drugs as well as the infecting agent H Pylori has been attributed as the prominent common etiological factor for peptic ulcers in patients. Distinguishing proof of Helicobacter pylori as the essential etiologic factor in the improvement of peptic ulcer illness and the perception that the frequency of H. pylori increments with age have brought up the issue of a potential synergistic connection between the presence of H. pylori contamination and NSAID use in the improvement of treatment in gastroenterology. Both H.Pylori and NSAIDs have, nevertheless, been appeared to affect the creation rate and the nature of gastric cyclic AMP, the bodily fluid layer, mucosal prostaglandins, blood stream, and platelet-activating factor.  Therefore, it is necessary to determine the risk factors such as age and history of peptic ulcers of the patient prior to prescribing. A co-prescription may be important to reduce the risk of peptic ulcers in patients of high risk. Since H.Pylori infection remains the world's most common chronic bacterial infection, it has been suggested that the establishment of a synergistic or additive effect of H.Pylori infection and NSAID use in the development of peptic ulcer is of great clinical importance as eradication of the bacterium is likely to reduce the risk of upper gastrointestinal complications in infected NSAID users. The prevention and overcoming of NSAIDS induced peptic ulcer and H Pylori induced peptic ulcer is embedded in the thorough understanding and assessment of pathophysiology and other underlying causes in each individual patient. There are wide range of studies that emphasize on the various methods of overcoming these conditions as well as understanding the co factors for the risk of ulcer. The main aim of the treatment is to protect the gastric mucosal layer from further eroding away and heal the mucosal ulcer as soon as possible to avoid further complications.

Export Citation Format

Share document.

Citation search

Your download is now in progress and you may close this window.

• Choose new content alerts to be informed about new research of interest to you
• Easy remote access to your institution's subscriptions on any device, from any location
• Save your searches and schedule alerts to send you new results
• Export your search results into a .csv file to support your research

Login or register to access this feature

Register now or learn more

Current Medical Research and Opinion

Start a new submission or continue a submission in progress

• Instructions for authors
• Editorial policies
• Editing services site
• Journal metrics
• Aims & scope
• Journal information
• Editorial board
• News & calls for papers
• Advertising information
• Latest articles

Current issue

• All volumes & issues
• Special issues
• Open access articles
• Most read articles
• Most cited articles
• New content alerts
• Subscription options & pricing

Ready to submit? Start a new submission or continue a submission in progress

Journal overview

• Aims and scope

Current Medical Research and Opinion (CMRO) is a MEDLINE-indexed, international journal that publishes research focused on new and existing drugs and therapies, best practices in patient care, developments in diagnostic medicine and medical technology, and innovations in medical and scientific publishing.

The journal aims to be a platform for high-quality, ethically sound clinical research, as well as provide a forum for guidance on effective and transparent publication and communication of medical research.

CMRO welcomes clinically relevant original research and reviews, brief reports, case series, and commentaries across all therapy areas, especially research pertaining to efficacy, equivalence, and safety. The journal also publishes research applicable to standards and practices in medical and scientific publishing. Pharmacoeconomic studies are considered if there is clear clinical relevance. Letters to the Editor and editorials should discuss articles previously published in CMRO.

Please note that CMRO does not publish Phase I, pre-clinical, and/or animal studies.

CMRO is committed to ensuring the accessibility and readability of medical and scientific literature. The journal encourages submission of plain language summaries, graphical and video abstracts, and infographics. Please see the Instructions for Authors for more information.

All manuscripts submitted to the journal are assessed for suitability by the Executive Editor; then peer-reviewed in a single-anonymized fashion.

If you would like to send a pre-submission enquiry regarding your manuscript’s suitability for publication, please contact CMRO’s Executive Editor, Dr. Mithi Ahmed.

Authors can publish gold open access in this journal and may choose to publish using our Accelerated Publication services.

Explore articles

• Open access

Explore the most recently published articles

Latest issues

• Recent issues

Previous issue

Reappraising the therapeutic role of beta-blockers across the cardiovascular continuum

Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms

• Advanced Search
• See Studies by Topic
• See Studies on Map
• How to Search
• How to Use Search Results
• How to Find Results of Studies
• How to Read a Study Record

• Learn About Studies
• Other Sites About Studies
• Glossary of Common Site Terms

• Submit Studies to ClinicalTrials.gov PRS
• Why Should I Register and Submit Results?
• FDAAA 801 and the Final Rule
• How to Apply for a PRS Account
• How to Register Your Study
• How to Edit Your Study Record
• How to Submit Your Results
• Frequently Asked Questions
• Support Materials
• Training Materials

• Selected Publications
• Clinical Alerts and Advisories
• Trends, Charts, and Maps
• Downloading Content for Analysis

• ClinicalTrials.gov Background
• About the Results Database
• History, Policies, and Laws
• ClinicalTrials.gov Modernization
• Media/Press Resources
• Linking to This Site
• Terms and Conditions
• Search Results
• Study Record Detail

An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older

• Study Details
• Tabular View
• No Results Posted

Inclusion Criteria:

Volunteers must meet the following inclusion criteria:

Type of participants

• Healthy volunteers or volunteers with a history of stable diseases that do not meet any of the criteria for non-inclusion in the study.

Other inclusion criteria

• Written informed consent of volunteers to participate in a clinical trial
• Volunteers who are able to fulfill the Protocol requirements (i.e., fill out a self-observation Diary, come to control visits).

Exclusion Criteria:

SARS-CoV-2 infection • A case of established COVID-19 disease confirmed by PCR and/or ELISA in the last 6 months.

Diseases or medical conditions

• Serious post-vaccination reaction (temperature above 40 C, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination.
• Burdened allergic history (anaphylactic shock, Quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.).
• Guillain-Barre syndrome (acute polyradiculitis) in the anamnesis.
• The axillary temperature at the time of vaccination is more than 37.0 ° C.
• Acute infectious diseases (recovery earlier than 4 weeks before vaccination) according to anamnesis.
• Donation of blood or plasma (in the amount of 450 ml or more) less than 2 months before inclusion in the study.
• Severe and/or uncontrolled diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, gastrointestinal tract, liver, kidneys, hematopoietic, immune systems.
• Is registered at the dispensary for tuberculosis, leukemia, oncological diseases, autoimmune diseases.
• Any confirmed or suspected immunosuppressive or immunodeficiency condition in the anamnesis.
• Splenectomy in the anamnesis.
• Neutropenia (decrease in the absolute number of neutrophils less than 1000/mm3), agranulocytosis, significant blood loss, severe anemia (hemoglobin less than 80 g/l) according to anamnesis.
• Anorexia according to anamnesis.

Prior or concomitant therapy

• Vaccination with any vaccine carried out within 30 days before vaccination / the first dose of the studied vaccine or planned administration within 30 days after vaccination / the last dose of the studied vaccine.
• Prior vaccination with an experimental or registered vaccine that may affect the interpretation of the study data (any coronavirus or SARS vaccines).
• Long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs (immunoregulatory peptides, cytokines, interferons, immune system effector proteins (immunoglobulins), interferon inducers (cycloferon) during the six months preceding the study, according to anamnesis.
• Treatment with systemic glucocorticosteroids (≥ 20 mg of prednisone, or an analog, for more than 15 days during the last month).
• Volunteers who received immunoglobulin preparations or blood transfusion during the last 3 months prior to the start of the study according to anamnesis.

Other non-inclusion criteria

• Participation in any other clinical trial within the last 3 months.

Exclusion criteria:

• Withdrawal of Informed consent by a volunteer;
• The volunteer was included in violation of the inclusion/non-inclusion criteria of the Protocol;
• Any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;
• Taking unauthorized medications (see section 6.2);
• The volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation;
• For administrative reasons (termination of the study by the Sponsor or regulatory authorities), as well as in case of gross violations of the Protocol that may affect the results of the study.
• For Patients and Families
• For Researchers
• For Study Record Managers
• Customer Support
• Accessibility
• Viewers and Players
• Freedom of Information Act
• HHS Vulnerability Disclosure
• U.S. National Library of Medicine
• U.S. National Institutes of Health
• U.S. Department of Health and Human Services

Comparative investigations of aftersintering of UO 2 fuel pellets

• Theory and Processes of Formation and Sintering of Powdered Materials
• Published: 06 May 2010
• Volume 51 , pages 173–176, ( 2010 )

Cite this article

• V. V. Basov 1  

23 Accesses

Explore all metrics

The basic parameters of comparative tests of UO 2 fuel pellets produced by the technology of powder metallurgy for aftersinterability using their repeated thermal treatment (aftersintering) in different gas media, namely, with and without humidification, are presented. The results of an evaluation of the level of aftersinterability of these pellets by different procedures is presented, they are analyzed, and a substantiation of the expediency of using this operation manual for evaluating afersintering without the humidification of the gas medium developed at the OAO Machine Building Works (MSZ), Elektrostal’, Moscow oblast, is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price includes VAT (Russian Federation)

Instant access to the full article PDF.

Rent this article via DeepDyve

Institutional subscriptions

Similar content being viewed by others

Investigation of (U, Th)O2 Fuel

I. S. Kurina, V. N. Rumyantsev & S. G. Samoilov*

Improvement of UO2 powder properties prepared from recycled aged fuel pellets

Fatah Mernache, Naima Boutarek, … Said Hadji

Preparation of powdered uranium oxides by microwave heating of substandard ceramic pellets of oxide nuclear fuel

Yu. M. Kulyako, T. I. Trofimov, … B. F. Myasoedov

An Acceptable Model and Related Statistical Methods for the Analysis of Fuel Densification , US Nuclear Regulatory Commission, Regulatory Guide 1.126.1978.

Freshley, M.D., Brite, D.M., Daniel, I.L., and Hart, P.E., J. Nucl. Mater , 1976, vol. 62, pp. 138–166.

Article   CAS   ADS   Google Scholar  

Radford, K. and Pope, I., J. Nucl. Mater , 1977, vol. 64, pp. 289–299.

Radford, K., et al., US Patent 4430276, 1984.

Basov, V.V., Metodika provedeniya ispytanii tabletok is dioksida urana na “dospekaemost’ “ (Procedure for Performance of the Tests of the Pellets made of Uranium Dioxide for Aftersinterability), Electrostal’: PO MSZ, 1994.

Google Scholar  

Bakhteev, A.N., Opredelenie termicheskoi stabil’nosti geometricheskikh razmerov toplivnykh tabletok tipa “V” i “R”: Metodika vypolneniya izmerenii (Determination of Thermal Stability of Geometric Sizes for Fuel Pellets of Types “V” and “R”: Procedure of Carrying out the Measurements), Moscow: VNIINM, 1992.

Basov, V.V., Opredelenie kharacteristik termicheskoi stabil’nosti toplivnykh tabletok tipov “R”, “R-E”, “V”: Metodika (tekhnologicheskaya instruktsiya) (Determination of Characteristics of Thermal Stability of Fuel Pellets of Types “R”, “R-E”, and “V”: Procedure (Technological Instruction), Electrostal’: OAO MSZ, 1999.

Kotel’nikov, R.B., Bashlykov, S.N., Kashtanov, A.I., et al., Vysokotemperaturnoe yadernoe toplivo (HighTemperature Nuclear Fuel), Moscow: Metallurgiya, 1978.

Download references

Author information

Authors and affiliations.

OAO Machine Building Works, ul. K. Marksa 12, Elektrostal’, Moscow oblast, 144001, Russia

V. V. Basov

You can also search for this author in PubMed   Google Scholar

Additional information

Original Russian Text © V.V. Basov, 2009, published in Izvestiya VUZ. Poroshkovaya Metallurgiya i Funktsional’nye Pokrytiya, 2009, No. 3, pp. 27–30.

About this article

Basov, V.V. Comparative investigations of aftersintering of UO 2 fuel pellets. Russ. J. Non-ferrous Metals 51 , 173–176 (2010). https://doi.org/10.3103/S1067821210020185

Download citation

Published : 06 May 2010

Issue Date : April 2010

DOI : https://doi.org/10.3103/S1067821210020185

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• fuel pellets
• model of fuel compaction
• repeated thermal treatment
• aftersintering
• aftersinterability
• procedure of carrying out aftersintering
• aftersintering installation
• stoichiometric composition
• isothermal sintering
• thermal shrinkage
• Find a journal
• Publish with us
• Track your research